Get the Stockscreener App
0.5302
0.71%
-0.0038
After Hours:
.53
-0.0002
-0.04%
Sangamo Therapeutics Inc stock is traded at $0.5302, with a volume of 9.05M.
It is down -0.71% in the last 24 hours and down -0.90% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.534
Open:
$0.5192
24h Volume:
9.05M
Relative Volume:
1.61
Market Cap:
$159.97M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.7069
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-2.05%
1M Performance:
-0.90%
6M Performance:
-38.33%
1Y Performance:
-33.58%
1-Day Range:
$0.47
$0.5424
1-Week Range:
$0.47
$0.5557
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5302 | 162.74M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Is Sangamo Therapeutics Inc. benefiting from interest rate changesPortfolio Value Report & Real-Time Market Sentiment Reports - khodrobank.com
Sangamo Therapeutics: A High-Conviction Biotech Play with a Clear Path to FDA Approval in 2026 - AInvest
Sangamo reports promising data for Fabry disease gene therapy - Investing.com
Sangamo Biosciences Reveals Promising Fabry Disease Study Results - TipRanks
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - The Manila Times
1.97 mL/min Kidney Function Improvement: Sangamo's One-Time Gene Therapy Could Transform Fabry Disease Care - Stock Titan
Will Sangamo Therapeutics Inc. stock recover after recent dropJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
Published on: 2025-09-04 02:16:59 - Newser
Will Sangamo Therapeutics Inc. outperform its industry peersJuly 2025 Volume & Momentum Based Trading Ideas - khodrobank.com
Chart based analysis of Sangamo Therapeutics Inc. trendsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
Evaluating Sangamo Therapeutics Inc. with trendline analysisAnalyst Downgrade & Community Consensus Stock Picks - Newser
Measuring Sangamo Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
What the charts say about Sangamo Therapeutics Inc. todayFed Meeting & Low Drawdown Trading Techniques - Newser
Will Sangamo Therapeutics Inc. benefit from current market trendsJuly 2025 Momentum & Technical Confirmation Alerts - khodrobank.com
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionEarnings Overview Summary & Smart Money Movement Alerts - Newser
What’s the profit margin of Sangamo Therapeutics Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - khodrobank.com
What MACD signals say about Sangamo Therapeutics Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Bull Run & Weekly High Potential Stock Alerts - Newser
Analyzing Sangamo Therapeutics Inc. with risk reward ratio charts2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Real time breakdown of Sangamo Therapeutics Inc. stock performance2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
Should I buy Sangamo Therapeutics Inc. stock now2025 Biggest Moves & Daily Growth Stock Investment Tips - khodrobank.com
Sangamo Therapeutics Inc.’s volatility index tracking explainedTrade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Is Sangamo Therapeutics Inc.’s ROE strong enough2025 Growth vs Value & Weekly Breakout Watchlists - khodrobank.com
Should you hold or exit Sangamo Therapeutics Inc. nowLayoff News & Risk Controlled Stock Pick Alerts - Newser
Sangamo Therapeutics Inc. stock trend outlook and recovery pathEarnings Growth Summary & Real-Time Chart Breakout Alerts - Newser
Technical analysis overview for Sangamo Therapeutics Inc. stock2025 Stock Rankings & Consistent Profit Alerts - Newser
Will Sangamo Therapeutics Inc. bounce back from current support2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Sangamo Therapeutics Inc. benefiting from innovation trendsJuly 2025 Patterns & Fast Exit and Entry Trade Guides - khodrobank.com
Is Sangamo Therapeutics Inc. a cyclical or defensive stockPortfolio Profit Report & Community Verified Watchlist Alerts - khodrobank.com
CEO Moves: Should I buy Sangamo Therapeutics Inc. stock now2025 Risk Factors & Weekly Stock Breakout Alerts - خودرو بانک
Does Sangamo Therapeutics Inc. fit your quant trading modelWeekly Trade Report & Weekly Hot Stock Watchlists - Newser
What is Sangamo Therapeutics Inc.’s valuation compared to sectorJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - khodrobank.com
Analyzing Sangamo Therapeutics Inc. with multi timeframe chartsInflation Watch & Real-Time Buy Signal Alerts - Newser
What are Sangamo Therapeutics Inc.’s recent SEC filings showingWeekly Stock Summary & Daily Growth Stock Tips - khodrobank.com
Developing predictive dashboards with Sangamo Therapeutics Inc. data2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Will Sangamo Therapeutics Inc. outperform the marketTrade Volume Report & Real-Time Volume Trigger Notifications - Newser
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):